Purpose. This study investigates the pre-operative sensitivity of a novel tumor marker for colorectal cancer (CRC). Methods. Atotal of 83 patients with colorectal cancer from 2014 to 2016 were enrolled in this retrospective study. All patients received colectomy with at least D2 lymph node dissection. DR-70 and carcinoembryonic antigen (CEA) levels were tested and included in the preoperative evaluation. Hematological and biochemical tests, pathology, and demographic data from the patients were analyzed to evaluate the correlation of DR-70 and CEA with the distribution of colorectal cancer. Results. Among the 83 patients, there were 12 (14.4 %) patients in pathological stage IV, 39 (46.9%) in stage III, 14 (16.8%) in stage II, and 18 (21.9%) in stage I. The sensitivity of DR-70 (＞ 1 mg/L) and CEA (＞ 5 μg/L) were 18.8% and 3.13% for the 32 patients in the early stages of colorectal cancer (stages I and II; p value = 0.04), while they were 23.5% and 49.0% for the 51 patients in the late stages (stages III and IV), respectively (p value = 0.19). However, for each of the four pathological stages, the sensitivity was not statistically significant. There was no correlation between CEA and DR-70 (p value = 0.661). There was no statistical significance in regard to the TNM staging. The perineural invasion was the only clinical characteristic that affected the sensitivity of DR-70. Conclusions. The pre-operative sensitivity of DR70 in our patient with DR-70 was 21.7%, and there is no correlation between CEA and DR-70.
- Colorectal cancer